253 related articles for article (PubMed ID: 14552702)
1. Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors.
Giovannini MG; Scali C; Prosperi C; Bellucci A; Pepeu G; Casamenti F
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):31-40. PubMed ID: 14552702
[TBL] [Abstract][Full Text] [Related]
2. Coxibs and Alzheimer's disease: should they stay or should they go?
Firuzi O; Praticò D
Ann Neurol; 2006 Feb; 59(2):219-28. PubMed ID: 16402383
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.
Casolini P; Catalani A; Zuena AR; Angelucci L
J Neurosci Res; 2002 May; 68(3):337-43. PubMed ID: 12111864
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs.
Townsend KP; Praticò D
FASEB J; 2005 Oct; 19(12):1592-601. PubMed ID: 16195368
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of COX inhibitors against beta-amyloid-induced neurotoxicity in human neuroblastoma cells.
Ferrera P; Arias C
Neurochem Int; 2005 Dec; 47(8):589-96. PubMed ID: 16169124
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions.
Pasinetti GM
J Neurosci Res; 1998 Oct; 54(1):1-6. PubMed ID: 9778144
[TBL] [Abstract][Full Text] [Related]
7. Role of cyclooxygenase-1 and -2 in health and disease.
Lipsky PE
Am J Orthop (Belle Mead NJ); 1999 Mar; 28(3 Suppl):8-12. PubMed ID: 10193997
[TBL] [Abstract][Full Text] [Related]
8. [Coxibs: highly selective cyclooxygenase-2 inhibitors. Part I. Clinical efficacy].
Burdan F; Korobowicz A
Pol Merkur Lekarski; 2003 Apr; 14(82):348-51. PubMed ID: 12868200
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration.
Salzberg-Brenhouse HC; Chen EY; Emerich DF; Baldwin S; Hogeland K; Ranelli S; Lafreniere D; Perdomo B; Novak L; Kladis T; Fu K; Basile AS; Kordower JH; Bartus RT
J Pharmacol Exp Ther; 2003 Jul; 306(1):218-28. PubMed ID: 12676885
[TBL] [Abstract][Full Text] [Related]
10. New insights into COX-2 biology and inhibition.
Patrignani P; Tacconelli S; Sciulli MG; Capone ML
Brain Res Brain Res Rev; 2005 Apr; 48(2):352-9. PubMed ID: 15850674
[TBL] [Abstract][Full Text] [Related]
11. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action.
Gasparini L; Ongini E; Wenk G
J Neurochem; 2004 Nov; 91(3):521-36. PubMed ID: 15485484
[TBL] [Abstract][Full Text] [Related]
12. Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease.
Hoozemans JJ; Veerhuis R; Rozemuller AJ; Eikelenboom P
Curr Drug Targets; 2003 Aug; 4(6):461-8. PubMed ID: 12866660
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention.
Kismet K; Akay MT; Abbasoglu O; Ercan A
Cancer Detect Prev; 2004; 28(2):127-42. PubMed ID: 15068837
[TBL] [Abstract][Full Text] [Related]
14. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
Tuynman JB; Hulscher JB; Steller EP; van Lanschot JJ; Richel DJ
Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2207-12. PubMed ID: 14640057
[TBL] [Abstract][Full Text] [Related]
15. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern.
Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI
Neuroscience; 2006 Sep; 141(3):1149-62. PubMed ID: 16753269
[TBL] [Abstract][Full Text] [Related]
16. An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease.
Imbimbo BP
Expert Opin Investig Drugs; 2009 Aug; 18(8):1147-68. PubMed ID: 19589092
[TBL] [Abstract][Full Text] [Related]
17. Expression of cyclooxygenase-2 in primary superficial bladder cancer tissue may predict risk of its recurrence after complete transurethral resection.
Okajima E; Uemura H; Ohnishi S; Tanaka M; Ohta M; Tani M; Fujimoto K; Ozono S; Okajima E; Hirao Y
Aktuelle Urol; 2003 Jul; 34(4):256-8. PubMed ID: 14566678
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of selective COX-2 inhibitors.
Capone ML; Tacconelli S; Sciulli MG; Patrignani P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):49-58. PubMed ID: 14552704
[TBL] [Abstract][Full Text] [Related]
19. Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease.
Gasparini L; Ongini E; Wilcock D; Morgan D
Brain Res Brain Res Rev; 2005 Apr; 48(2):400-8. PubMed ID: 15850679
[TBL] [Abstract][Full Text] [Related]
20. The selective cyclooxygenase-2 inhibitor rofecoxib suppresses brain inflammation and protects cholinergic neurons from excitotoxic degeneration in vivo.
Scali C; Giovannini MG; Prosperi C; Bellucci A; Pepeu G; Casamenti F
Neuroscience; 2003; 117(4):909-19. PubMed ID: 12654342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
